Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Abbildungen und Graphiken
Schramm GAK, Waldmann-Rex S  
Effects of 2 mg Chlormadinone Acetate/0.03 mg Ethinylestradiol in Primary Dysmenorrhoea: The BEDY (Belara(R) Evaluation on Dysmenorrhea) Study - an Open, Non-Comparative, Non-Interventional Observational Study with 4,842 Women

Journal für Reproduktionsmedizin und Endokrinologie - Journal of Reproductive Medicine and Endocrinology 2010; 7 (Sonderheft 1): 112-118

Volltext (PDF)    Summary    Abbildungen   


Abbildung
 
BEDY-Study - Age distribution
Abbildung 1: Age distribution of women in the efficacy sample (n = 4514).


Keywords: Kontrazeption
 
 
BEDY Study - Dysmenorrhoea
Abbildung 2: Intensity of dysmenorrhoea symptoms before and after the administration of 2 mg chlormadinone acetate/ 0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (n = 3857).


Keywords: Kontrazeption
 
 
BEDY Study - Analgesic Treatment
Abbildung 3: Incidence and frequency of analgesic treatment due to dysmenorrhoea, before and after the administration of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (n = 3860).


Keywords: Kontrazeption
 
 
BEDY Study - Dysmenorrhoea
Abbildung 4: Absence from school or work due to dysmenorrhoea, before and after the administration of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (n = 3722).


Keywords: Kontrazeption
 
 
BEDY Study - Skin and Hair Symptoms
Abbildung 5: Incidence and intensity of skin and hair symptoms, before and after the administration of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown (n = 3951, Acne Prone Skin; n = 3934, Greasy Hair).


Keywords: Kontrazeption
 
 
BEDY Study - Cycle-Related Disorders
Abbildung 6: Incidence of moderate to severe symptoms in other cycle-related disorders, before and after the administration of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol (CMA/EE). Results from patients with valid ratings at baseline and after 6 cycles/blister packs of CMA/EE treatment are shown.


Keywords: Kontrazeption
 
 
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung